Elanco Animal Health (NASDAQ:ELAN) Lowered to Hold at Zacks Investment Research
According to Zacks, “Elanco Animal Health Incorporated operates as an animal health care company. It develops, manufactures and markets products for companion and food animals. Elanco Animal Health Incorporated is based in Greenfield, United States. “
ELAN has been the subject of several other reports. UBS Group boosted their price objective on shares of Fortis from C$54.00 to C$55.00 in a research report on Wednesday, March 20th. Bank of America assumed coverage on shares of DENTSPLY SIRONA in a research report on Monday, March 18th. They set a buy rating and a $57.00 price objective for the company. BMO Capital Markets boosted their price objective on shares of Sun Life Financial from C$58.00 to C$60.00 in a research report on Friday, May 10th. Guggenheim assumed coverage on shares of Elanco Animal Health in a research report on Wednesday, May 22nd. They set a neutral rating for the company. Finally, Morgan Stanley set a €52.00 ($60.47) price objective on shares of Vonovia and gave the company a buy rating in a research report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the stock. Elanco Animal Health presently has a consensus rating of Hold and an average target price of $33.56.
Elanco Animal Health (NASDAQ:ELAN) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.22 by $0.03. The firm had revenue of $731.10 million for the quarter, compared to analyst estimates of $743.40 million. During the same quarter in the prior year, the firm earned $0.33 earnings per share. The firm’s revenue for the quarter was down .7% on a year-over-year basis.
In related news, Director John P. Bilbrey purchased 7,750 shares of the stock in a transaction dated Monday, May 13th. The stock was bought at an average cost of $32.39 per share, for a total transaction of $251,022.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Several large investors have recently made changes to their positions in the company. Primecap Management Co. CA increased its holdings in shares of Elanco Animal Health by 516.8% during the first quarter. Primecap Management Co. CA now owns 30,607,906 shares of the company’s stock worth $981,596,000 after buying an additional 25,645,707 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Elanco Animal Health by 618.1% during the first quarter. BlackRock Inc. now owns 19,559,113 shares of the company’s stock worth $627,262,000 after buying an additional 16,835,410 shares in the last quarter. Amundi Pioneer Asset Management Inc. increased its holdings in shares of Elanco Animal Health by 88.6% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 10,878,124 shares of the company’s stock worth $348,861,000 after buying an additional 5,111,146 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of Elanco Animal Health during the first quarter worth $341,261,000. Finally, OppenheimerFunds Inc. acquired a new position in shares of Elanco Animal Health during the first quarter worth $310,058,000.
About Elanco Animal Health
There is no company description available for Elanco Animal Health Inc
Further Reading: What is a Candlestick Chart?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.